Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
|Articles|March 2, 2002
She is not 18; can she provide informed consent?
Jane, a very mature 17-year-old adolescent, presents to Dr. Jones forremoval of a facial nevus. Dr. Jones discusses the risk/benefit ratio ofsuch an excision. In the course of the discussion, he determines that sheis working a full-time job and lives with her boyfriend at home with herparents. She signs a standard consent form. Dr. Jones does not realize thatshe is 17; he did not ask. Ultimately she is not happy with the scar andwishes to sue her dermatologist. The basis of her suit is that at age 17she was not able to provide informed consent. Dr. Jones is aware that, asa general rule, a patient must be 18 years of age to provide informed consent.However, he contends that Jane was highly intelligent, articulate and hada better understanding of the procedure than some 19 year olds might have.Can Jane, as an adolescent, give informed consent?
Advertisement
Advertisement
Related to this article
Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
5